Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison
| العنوان: | Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison |
|---|---|
| المؤلفون: | Brent J. Small, Eduardo M. Sotomayor, Kristin M. Phillips, Paul B. Jacobsen, Morgan R. Lee, Jeffrey E. Lancet, Javier Pinilla-Ibarz, Sara Tinsley, Lubomir Sokol, Kendra Sweet, Heather S. L. Jim, Rami S. Komrokji |
| المصدر: | Supportive Care in Cancer. 21:1097-1103 |
| بيانات النشر: | Springer Science and Business Media LLC, 2012. |
| سنة النشر: | 2012 |
| مصطلحات موضوعية: | Adult, Male, Oncology, medicine.medical_specialty, Adolescent, Nausea, Dasatinib, Antineoplastic Agents, Piperazines, Young Adult, Quality of life, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Surveys and Questionnaires, hemic and lymphatic diseases, Internal medicine, Outcome Assessment, Health Care, medicine, Humans, Protein Kinase Inhibitors, Fatigue, Aged, Aged, 80 and over, Depression, business.industry, Standard treatment, Myeloid leukemia, Imatinib, Middle Aged, United States, respiratory tract diseases, Thiazoles, Pyrimidines, Imatinib mesylate, Nilotinib, Case-Control Studies, Benzamides, Immunology, Imatinib Mesylate, Quality of Life, Female, medicine.symptom, business, medicine.drug |
| الوصف: | Tyrosine kinase inhibitors (TKIs) are now standard treatment for chronic myeloid leukemia (CML). While TKIs have less toxicity than previous treatments, they have side effects that can impact quality of life (QOL).This study compared CML patients taking a TKI for an average of 4.01 years (range 0.50-9.79 years) to age- and gender-matched controls with no history of cancer on measures of symptom burden, depression, fatigue, sleep, and health-related QOL.Compared to controls (n = 62), CML patients (n = 62) taking a TKI (imatinib 55 %, nilotinib 31 %, and dasatinib 14 %) reported significantly worse fatigue severity (p .001), fatigue interference (p .001), depression (p = .007), symptom burden (p .001), and physical QOL (p .001). TKI patients were also more likely meet established cutoffs for clinically meaningful fatigue (p values .001) and depression (p = .004). There were no differences in mental QOL or sleep (p values .010). Regarding specific symptoms, TKI patients were more likely to report nausea, diarrhea, itching, skin changes, swelling of arms or legs, and not looking like themselves (p values .001).These data suggest the need for interventions to address QOL in CML patients taking TKIs. |
| تدمد: | 1433-7339 0941-4355 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d84f5b89cf5195fba32ead8ad842cfa7Test https://doi.org/10.1007/s00520-012-1630-5Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....d84f5b89cf5195fba32ead8ad842cfa7 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14337339 09414355 |
|---|